Assessment of antimicrobial activity of melittin encapsulated in bicontinuous microemulsions prepared using renewable oils
Data files
Jan 04, 2023 version files 1.23 MB
-
CD_Fluoresc_data.xlsx
38.09 KB
-
README.md.docx
34.48 KB
-
saxs_data.xlsx
1.14 MB
-
Winsor_III_vol_fracts.xlsx
16.61 KB
Abstract
The objective of this study is to demonstrate that melittin, a well-studied antimicrobial peptide (AMP), can be solubilized in an active form in bicontinuous microemulsions (BMEs) that employ biocompatible oils. The systems investigated consisted of Winsor-III and -IV BME phases composed of Water/Aerosol-OT (AOT)/Polysorbate 85/isopropyl myristate and a Winsor-IV BME employing Polysorbate 80 and limonene. We found that melittin resided in an a-helix-rich configuration and was in an apolar environment for the AOT/Polysorbate 85 Winsor-III system, suggesting that melittin interacted with the surfactant monolayer and was in an active conformation. An apolar environment was also detected for melittin in the two Winsor-IV systems, but to a lesser extent than the Winsor-III system. Small-angle X-ray scattering analysis indicated that melittin at a concentration of 1.0 g/Laq in the aqueous subphase of the Winsor-IV systems led to the greatest impact on the BME structure (e.g., decrease of quasi-periodic repeat distance and correlation length and induction of interfacial fluidity). The antimicrobial activity of the Polysorbate 80 Winsor-IV system was evaluated against several bacteria prominent in chronic wounds and surgical site infections (SSIs). Melittin-free BMEs inhibited the growth of all tested bacteria due to its oil, limonene, while the inclusion of 1.0 g/Laq of melittin in the BMEs enhanced the activity against several bacteria. A further increase of melittin concentration in the BMEs had no effect. These results demonstrate the potential utility of BMEs as a delivery platform for AMPs and other hydrophilic and lipophilic drugs to inhibit antibiotic-resistant microorganisms in chronic wounds and SSIs.
Methods
Collected through measurements of: A) volume fractions for Winsor-III microemulision systems; B) Bradford assay to measure protein concentration; c) circular dichroism spectroscopy; D) fluescence spectroscopy; E) small-angle s-ray scattering (SAXS); F) model fitting of SAXS data; G) well diffusion bioassays. There was no further processing performed on the data.
Usage notes
Microsoft Excel